SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention

• Published in: Journal of cardiovascular pharmacology Vol. 76; no. 2; p. 189
• Main Authors: Tcheng, James E, Gibson, Michael, Krucoff, Mitchell W, Patel, Manesh R, Ajit, Mullasari, Hiremath, Jagdish, Ponde, Chandrashekhar, Ramsaran, Eddison, Clark, Geoffrey, Lader, Alan S, Beeuwkes, 3rd, Reinier
• Format: Journal Article
• Language: English
• Published: United States 01.08.2020
• Subjects: Aged; Angioplasty, Balloon, Coronary - adverse effects; Biomarkers - blood; Cardiovascular Agents - adverse effects; Cardiovascular Agents - pharmacokinetics; Cardiovascular Agents - therapeutic use; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - therapy; Creatine Kinase, MB Form - blood; Dipeptides - adverse effects; Dipeptides - pharmacokinetics; Dipeptides - therapeutic use; Double-Blind Method; Female; Humans; India; Male; Middle Aged; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Myocytes, Cardiac - pathology; Necrosis; Prospective Studies; Thioctic Acid - adverse effects; Thioctic Acid - analogs & derivatives; Thioctic Acid - pharmacokinetics; Thioctic Acid - therapeutic use; Time Factors; Treatment Outcome; Troponin T - blood; United States; United States; India

The natural molecule α-lipoic acid has been shown to be partially cytoprotective through antioxidant and antiapoptotic mechanisms. To obtain an initial assessment of the safety and potential efficacy of a synthetic derivative, CMX-2043, in preventing ischemic complications of percutaneous coronary i...